Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CRMD @ Stockcharts
This out the door quickly for 2014- near 10% gainer!
http://seekingalpha.com/article/1923361-cormedix-an-interesting-play-in-the-catheter-care-space?source=yahoo
http://finance.yahoo.com/news/cormedix-receives-minutes-neutrolin-pre-145100115.html
Horizon Pharma Announces Availability of Horizon-Labeled VIMOVO(R) in the United States
About VIMOVO
VIMOVO® (naproxen / esomeprazole magnesium) is a proprietary fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID) and immediate-release esomeprazole, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not recommended for use in children younger than 18 years of age. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond 6 months. VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by a health care provider.
http://finance.yahoo.com/news/horizon-pharma-announces-availability-horizon-123000055.html
HEB @ Stockcharts
Nice 9.5% gainer today w/ 2.3M shares traded!
http://finance.yahoo.com/news/centers-disease-control-urges-preparation-133000322.html
Thought to stop in with a few choices-BONE (.51) /MELA (.65)-NVLX (.10) and SBFM (.17)
GLTA
Investor 100
Bone @ Stockcharts
Solid 15% gainer passing the 50MA with MFI moving up!
http://bacterin.com/news/
ATHX @ Stockcharts
Nice MOMO at 6% and one to follow in 2014!
http://finance.yahoo.com/news/athersys-confirms-completion-patient-enrollment-120000164.html
http://finance.yahoo.com/news/athersys-multistem-r-stem-cell-120000246.html
The MultiStem therapy for the prevention of GvHD has also previously been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).
APRI @ Stockcharts
Solid 16.5% gainer passing the 200MA!
http://seekingalpha.com/article/1914871-apricus-biosciences-future-profits-from-sexual-health-research-and-marketing?source=yahoo
AEZS @ Stockcharts
Nice 8% gainer today and another 3.4% AH!
http://seekingalpha.com/article/1895331-aeterna-zentaris-mispriced-1-biotech-stock-with-limited-downside-risk-and-big-upside-potential?source=yahoo
Form 4 @ HZNP
Nice confirmation of confidence with an inside purchase!
http://openinsider.com/search?q=hznp
http://www.sec.gov/Archives/edgar/data/1492426/000122520813025614/xslF345X03/doc4.xml
APRI @ Stockcharts
Solid 10% gainer..follow the money MFI!
http://finance.yahoo.com/news/apricus-announces-national-phase-approval-213827373.html
DRRX @ Stockcharts
Bottoms up...nice 4% gainer.
http://finance.yahoo.com/news/durect-corporation-announces-third-quarter-210500393.html
About DURECT Corporation
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDURâ„¢, ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
CIBH @ Stockcharts
Nice 23% gainer on solid news!
http://finance.yahoo.com/news/cibm-bank-acquire-avenue-mortgage-210101869.html
ACRX @ Stockcharts
Nice 10% gainer on solid news!
http://finance.yahoo.com/news/acelrx-secures-40-million-credit-123000002.html
NBY @ Stockcharts
Solid 10% gainer on the news!
http://finance.yahoo.com/news/novabay-pharmaceuticals-announces-plan-reinitiate-130000963.html
OMER @ Stockcharts
Like the designation and opportunity in 2014!
Orphan designation by the FDA is granted to promote the development of drugs that target conditions affecting 200,000 or fewer U.S. patients annually and that are expected to provide significant therapeutic advantage over existing treatments. Orphan designation qualifies a company for benefits that apply across all stages of drug development, including accelerated approval process, seven years of market exclusivity following marketing approval, tax credits on U.S. clinical trials, eligibility for orphan drug grants, and waiver of certain administrative fees.
http://finance.yahoo.com/news/fda-grants-orphan-drug-designation-120000395.html
EXEL @ Stockcharts
Solid news out of Europe..storyline looking good!
http://finance.yahoo.com/news/cometriq-cabozantinib-receives-positive-opinion-212100774.html
DARA @ Stockcharts
Solid 18% gainer going after the 200 (MA).
http://finance.yahoo.com/news/dara-biosciences-completes-breast-cancer-133000249.html
DARA is focused on expanding its portfolio of oncology supportive care products in the United States, via in-licensing and/or partnering of complementary late-stage and approved products. In addition, the company wishes to identify a strategic partner for the clinical development of KRN5500, currently in Phase 2 for the treatment of chronic, treatment refractory, chemotherapy-induced peripheral neuropathy (CCIPN). The FDA has designated KRN5500 as a Fast Track Drug, and DARA is seeking orphan status for the treatment of CCIPN.
PACB @ Stockcharts
Nice 7.5% gainer moving up...nice inside buy too!
http://www.forbes.com/sites/marketnewsvideo/2013/11/22/friday-1122-insider-buying-report-pacb-carb/?partner=yahootix
http://investor.pacificbiosciences.com/releasedetail.cfm?ReleaseID=755828
RNN @ Stockcharts
Nice 21% gainer on today's news
http://finance.yahoo.com/news/rexahn-receives-method-patent-treatment-130000712.html
ROCKVILLE, Md.--(BUSINESS WIRE)--
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate SupinoxinTM (RX-5902). Rexahn had previously received a composition of matter patent from the United Stated Patent and Trademark Office covering the structure of Supinoxin.
ISCO @ Stockcharts
Solid news gainer with a 23% gainer...on a vote of confidence!
http://finance.yahoo.com/news/international-stem-cell-corporation-announces-133000095.html
ECTE @ Stockcharts
Solid gainer on the news $3.56 (AH) 21% gainer
http://finance.yahoo.com/news/echo-therapeutics-announces-strategic-partnership-224200554.html
GALE @ Stockcharts
Solid 12% gainer!
http://www.fool.com/investing/general/2013/11/26/whats-behind-galena-biopharmas-recent-run.aspx
ALIM @ Stockcharts
U.K.'s NICE Issues Final Guidance Recommending Alimera Sciences' ILUVIEN®
http://finance.yahoo.com/news/u-k-nice-issues-final-120000028.html
SNGX @ Stockcharts
Solid news this morning.
Clinical Trial Supported by $300,000 NCI Grant
http://finance.yahoo.com/news/soligenix-announces-initiation-phase-2-121500697.html
IDIX @ Stockcharts
Solid steady movement!
Phase 2 news:http://finance.yahoo.com/news/idenix-pharmaceuticals-announces-initiation-enrollment-120000177.html
ACRX @ Stockcharts
Nice 11% jump with MFI warming up!
http://seekingalpha.com/article/1866681-acelrx-huge-potential-with-limited-risk?source=yahoo